At present, the word "sulforaphane" is used in PubMed, and more than 900 papers have been published/kloc-0 (visited PubMed on February 4th, 20th19th). However, the number of clinical trials using fresh or processed broccoli buds is limited (table 1). Not all experiments have quantitatively explained the biological activity content of intervention materials. Therefore, it is difficult to explain their findings clinically.

Table 1. The dosage of sulforaphane in specific clinical trials is from low to high.

Table 1 illustrates the dosage range of SFN used in selected clinical trials, where the endpoint is common human diseases or disease biomarkers. Despite the short duration of these trials and the small number of participants, these data make us more aware of the potential of SFN as a clinical intervention. Although the dosage form, research population and end point of the selected trial are different, there is a pattern, that is, the dosage of SFN is about 18 mg per day, and the dosage of SFN is 27-40 mg for type 2 diabetes, which can achieve clinical effects in asthma and other situations.

References:

[1] A. S. Axelsson, E. Tubbs, B. Mecham et al., "sulforaphane reduces hepatic glucose production and improves blood glucose control in patients with type 2 diabetes", Science Journal.

Ethnic Medicine, Volume 9, No.394, Article eaah4477, 20 17.

[2] K. Singh, S. L. Connors, E. A. Macklin, et al., "sulforaphane in the treatment of autism spectrum disorder (ASD)," Proceedings of the National Academy of Sciences,No.11vol., No.43,No./kloc-0.